ArticleBritish journal of pharmacology2012
The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.
Article in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022Pooled it
- Article
- Presynaptic nanoscale components of retrograde synaptic signaling.Science advances · 2024Article
- Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery.International journal of molecular sciences · 2023Review
- Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.Molecular diversity · 2023Article
- Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.International journal of molecular sciences · 2022Review
- Effects of cannabinoids on ligand-gated ion channels.Frontiers in physiology · 2022Review
- CB1R activation in nucleus accumbens core promotes stress-induced reinstatement of cocaine seeking by elevating extracellular glutamate in a drug-paired context.Scientific reports · 2021Article
- Experimental GABA A Receptor Agonists and Allosteric Modulators for the Treatment of Focal Epilepsy.Journal of experimental pharmacology · 2021Review
- Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.Advances in experimental medicine and biology · 2021Review
- Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine,Nutrients · 2020Article
- Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission.Scientific reports · 2018Article
- The quest for endothelial atypical cannabinoid receptor: BKVascular pharmacology · 2018Article
- Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.Sleep · 2017Article
- Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.British journal of pharmacology · 2016Article
- Sigma receptors [σRs]: biology in normal and diseased states.Journal of receptor and signal transduction research · 2016Article
- Effects of the cannabinoid CB₁ receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats.Drug and alcohol dependence · 2014Article
- Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.Journal of neural transmission (Vienna, Austria : 1996) · 2014Article
- The biarylpyrazole compound AM251 alters mitochondrial physiology via proteolytic degradation of ERRα.Molecular pharmacology · 2013Article
- The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.British journal of pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeRimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments. We intended to show that these drugs did not act at GABA(A) receptors but found a significant positive allosteric modulation instead. EXPERIMENTAL APPROACH: Recombinant GABA(A) receptors were expressed in Xenopus oocytes. Receptors were exposed to AM251 or rimonabant in the absence and presence of GABA. Standard electrophysiological techniques were used to monitor the elicited ionic currents. KEY
resultsAM251 dose-dependently potentiated responses to 0.5 µM GABA at the recombinant α(1) β(2) γ(2) GABA(A) receptor with an EC(50) below 1 µM and a maximal potentiation of about eightfold. The Hill coefficient indicated that more than one binding site for AM251 was located in this receptor. Rimonabant had a lower affinity, but a fourfold higher efficacy. AM251 potentiated also currents mediated by α(1) β(2) , α(x) β(2) γ(2) (x = 2,3,5,6), α(1) β(3) γ(2) and α(4) β(2) δ GABA(A) receptors, but not those mediated by α(1) β(1) γ(2) . Interestingly, the CB(1) receptor antagonists LY320135 and O-2050 did not significantly affect α(1) β(2) γ(2) GABA(A) receptor-mediated currents at concentrations of 1 µM. CONCLUSIONS AND IMPLICATIONS: This study identified rimonabant and AM251 as positive allosteric modulators of GABA(A) receptors. Thus, potential GABAergic effects of commonly used concentrations of these compounds should be considered in in vitro experiments, especially at extrasynaptic sites where GABA concentrations are low. LINKED ARTICLES: This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.